American Academy of Pediatrics Backs NGS Testing for Developmental Delay, Intellectual Disability GeneDx's stock surged on the recommendations, with analysts estimating that the changes unlock a roughly $2.6 billion market segment.

American Academy of Pediatrics Backs NGS Testing for Developmental Delay, Intellectual Disability. #PediatricGeneticTesting #NGStesting #WGS #WES #AmericanAcademyPediatrics #NeurodevelopmentalDisorders @genomeweb.bsky.social‬
www.genomeweb.com/molecular-di...